Breast Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China.
Multi-omics Laboratory of Breast Diseases, State Key Laboratory of Biotherapy, National Collaborative, Innovation Center for Biotherapy, West China Hospital, Sichuan University, China.
Phys Chem Chem Phys. 2024 Mar 20;26(12):9155-9169. doi: 10.1039/d3cp03923d.
Src homology 2-domain-containing tyrosine phosphatase 2 (SHP2) is a non-receptor protein tyrosine phosphatase that is widely expressed in a variety of cells and regulates the immune response of T cells through the PD-1 pathway. However, the activation mechanism and allosteric effects of SHP2 remain unclear, hindering the development of small molecule inhibitors. For the first time, in this study, the complex structure formed by the intact PD-1 tail and SHP2 was modeled. The molecular recognition and conformational changes of inactive/active SHP2 ITIM/ITSM were compared based on prolonged MD simulations. The relative flexibility of the two SH2 domains during MD simulations contributes to the recruitment of ITIM/ITSM and supports the subsequent conformational change of SHP2. The binding free energy calculation shows that inactive SHP2 has a higher affinity for ITIM/ITSM than active SHP2, mainly because the former's N-SH2 refers to the α-state. In addition, a significant decrease in the contribution to the binding energy of certain residues (, R32, S34, K35, T42, and K55) of conformationally transformed SHP2 contributes to the above result. These detailed changes during conformational transition will provide theoretical guidance for the molecular design of subsequent novel anticancer drugs.
Src 同源结构域 2 含酪氨酸磷酸酶 2(SHP2)是一种广泛表达于多种细胞的非受体酪氨酸磷酸酶,通过 PD-1 途径调节 T 细胞的免疫反应。然而,SHP2 的激活机制和变构效应仍不清楚,这阻碍了小分子抑制剂的开发。在这项研究中,我们首次构建了完整 PD-1 尾部与 SHP2 形成的复合物结构。通过延长 MD 模拟,比较了无活性/活性 SHP2 ITIM/ITSM 的分子识别和构象变化。MD 模拟过程中两个 SH2 结构域的相对灵活性有助于 ITIM/ITSM 的募集,并支持 SHP2 的后续构象变化。结合自由能计算表明,无活性 SHP2 与 ITIM/ITSM 的亲和力高于活性 SHP2,主要是因为前者的 N-SH2 指向α态。此外,构象转化 SHP2 中某些残基(,R32,S34,K35,T42 和 K55)对结合能的贡献显著降低,导致了上述结果。这些构象转换过程中的详细变化将为后续新型抗癌药物的分子设计提供理论指导。